«RADIATION DOSE RATES FROM PATIENTS RECEIVING IODINE-131 THERAPY IN THE RABAT CHU» T.KALONJI, A.ELYAHYAOUI, S.BOUHLASSA, F.IMANI, N.

Similar documents
Review of the radiological protection discharge protocol used in the treatment of thyroid cancer in the Virgen del Rocio University Hospitals

Radiation Protection Principles for Radioiodine Therapy

Summary of Patient Release after Radioiodine Therapy Research Review

Austin Radiological Association Nuclear Medicine Procedure THERAPY FOR THYROID CANCER (I-131 as Sodium Iodide)

High-Dose Radioiodine Outpatient Treatment: An Initial Experience in Thailand

Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma.

EXPOSURE FROM DIAGNOSTIC NUCLEAR MEDICINE PROCEDURES. 14 Victor Babes Street, RO-6600, Iasi, Romania

FUNDAMENTAL SAFETY OVERVIEW VOLUME 2: DESIGN AND SAFETY CHAPTER S: RISK REDUCTION CATEGORIES 3. RADIOLOGICAL CONSEQUENCES OF SEVERE ACCIDENTS

Description of the consecutive stages (which took place from December 2002 to July 2003)

Iodine-131 Saliva Secretion in Ablation Treatment for Thyroid Cancer Patients

Effects of Early Liothyronine Consumption After Radioiodine Therapy on Accumulated Dose and Exposure Rate in Patients With Thyroid Carcinoma

Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer

medicinska revija medical review

EANM Procedure Guideline For Therapy with Iodine-131

Nuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging

Nuclear Regulatory Commission guidance on release of radioactive patients

nuclear science and technology

Medical Physics 4 I3 Radiation in Medicine

Prophylactic Use of Potassium Iodide (KI) in Radiological Emergencies*: Information for Physicians

Imaging in Pediatric Thyroid disorders: US and Radionuclide imaging. Deepa R Biyyam, MD Attending Pediatric Radiologist

Inpatient Admission for Radiation Therapy

Cigna Medical Coverage Policy

Radiation Safety Precautions in 131 I Therapy of Graves Disease Based on Actual Biokinetic Measurements

Radioiodine Therapy for Thyrotoxicosis (Hyperthyroidism)

Procedure: I-131 Tx for Hyperthyroidism

Abstract. Methods CONJ 13/4/03 RCSIO 13/4/03

Analysis on Distribution of Effective Dose Rate around Patients for Treatment of Thyroid Cancer with I-131

Diagnostic Reference Levels (DRLs)

Nuclear Medicine: Basics to therapy

Internal Dosimetry of Human Brain for 99m tc and 131 I Using Nuclear Imaging in Bangladesh

radioactive iodine (iodine-131) Knowing the benefits and risks of radioactive iodine enables you and your doctor to decide WHAT S RIGHT FOR YOU.

Current and Planned Reports and Conferences of the National Council on Radiation Protection and Measurements

Radiation Safety For Anesthesiologists. R2 Pinyada Pisutchareonpong R2 Nawaporn Sateantantikul Supervised by Aj Chaowanan Khamtuicrua

Colour on-line figures None Colour print figures None

EXPOSURE RATE IN HOT WAITING AREA OF SMALL BUT BUSY NUCLEAR MEDICINE DEPARTMENT: METER MATTERS

Current and Planned NCRP Activities

An investigation of the effect of ionising radiation on nurses and their patients during dialysis

Approach to Thyroid Nodules

Radiation Safety Precautions in the Treatment of Patients with Radioiodine ( 131 I): Best Practice Guidelines of the American Thyroid Association

Patient Guide to Radioiodine Treatment For Thyrotoxicosis (Overactive Thyroid Gland or Hyperthyroidism)

Radiation Dose Rates from Patients Administrated Radiopharmaceuticals Used for Brain Blood Flow Investigation.

AN INTRODUCTION TO NUCLEAR MEDICINE

Treatment of Graves Disease by the Atomic Cocktail by Malcolm R. Powell, M.D., F.A.C.P, F.A.C.N.P

QUANTIFICATION OF THE RISK-REFLECTING STOCHASTIC AND DETERMINISTIC RADIATION EFFECTS

Determination of Beta Radiation Dose to the Thyroid Gland from the Ingestion of 131 I by Patients

I-123 Thyroid Scintigraphy

Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan

Exposure of the Belgian Population to Ionizing Radiation

might be due to a direct action on the thyroid, like that of the thiouracil

Integrated Research Application System (IRAS)

High Dose Radioactive Iodine (I-131) Therapy for Treatment of Thyroid Cancer for Out-Patients

1. Protocol Summary Summary of Trial Design. IoN

Release of Patients or Human Research Subjects Administered Radioactive Materials

Nuclear Medicine Head and Neck Region. Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine

Using Monte Carlo Method for Evaluation of kvp & mas variation effect on Absorbed Dose in Mammography

Sodium Iodide I 131 Solution. Click Here to Continue. Click Here to Return to Table of Contents

Excretion Factors: the percentage of administered radioactivity released to sewer for routinely used radiopharmaceuticals.

Controlling Natural Occurring Radioactive Material (NORM) Exposure

RESEARCH ARTICLE. Factors Predicting Early Release of Thyroid Cancer Patients from the Isolation Room after Radioiodine-131 Treatment

Adjuvant therapy for thyroid cancer

Supplementary Information. Renseignements supplémentaires. Exposé oral. Oral Presentation. Presentation from Jerry Cuttler

Treatment of Hyperthyroidism With Iodine-131

FDG-18 PET/CT - radiation dose and dose-reduction strategy

An Open Letter To IAEA

Radiation exposure of the Yazd population from medical conventional X-ray examinations

Telecom Order CRTC

High Dose Radioactive Iodine (I-131) Therapy for Treatment of Thyroid Cancer

Radiation physics and radiation protection. University of Szeged Department of Nuclear Medicine

Ionizing Radiation. Michael J. Vala, CHP. Bristol-Myers Squibb

Simulating Potential Layouts for a Proton Therapy Treatment Center

Dollars and Sense: Are We Overshielding Imaging Facilities? Part 2

What is the current risk of radiation-related health problems in Japan to those near the reactor at the time, and those in other parts of Japan?

Public Perceptions of the Iodine Tablets Distribution Around French Nuclear Power Plants

PRINCIPLES AND METHODS OF RADIATION PROTECTION

COMMISSION STAFF WORKING DOCUMENT IMPACT ASSESSMENT. Accompanying the document COUNCIL DIRECTIVE

Medical Use of Radioisotopes

THYROID IMAGING STUDY (Tc-99m as Sodium Pertechnetate)

International Atomic Energy Agency Department of Nuclear Safety and Security

Status of Regulatory Infrastructure in Arab Countries. Tunis, 13 March 2013

Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases

METROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY. Glenn Flux

What you need to know about Thyroid Cancer

Radiotherapy in feline and canine head and neck cancer

Impact of digitalization of mammographic units on average glandular doses in the Flemish Breast Cancer Screening Program

Thyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA

Evaluation of Personal Shields Used in Selected Radiology Departments

A Simple Model for Establishing Exemption Limits

RERF s Views on Residual Radiation 8 December 2012 Radiation Effects Research Foundation. Introduction

Radiation Exposure to Staff Using PET/CT Facility

MEDICAL ASSISTANCE IN DYING: LEGAL FACTS ON THE THREE OUTSTANDING AREAS

A STUDY ON SOME PHYSICAL PARAMETERS RELATED TO IMAGE QUALITY AND RADIATION SAFETY IN DIAGNOSTIC RADIOLOGY

Chapter 22 THYROID UPTAKE TEST. R.D. Ganatra

저작권법에따른이용자의권리는위의내용에의하여영향을받지않습니다.

General Nuclear Medicine

CLINICAL CONSIDERATIONS FOR I-131 THERAPY

American College of Radiology ACR Appropriateness Criteria

Austin Radiological Association Nuclear Medicine Procedure THYROID UPTAKE MEASUREMENT (I-123 or I-131 as Sodium Iodide)

Endocrinology Clinical Privileges REAPPOINTMENT Effective from July 1, 2015 to June 30, 2016

Hyperthyroidism in Cats

IMAGING MEDICAL PHYSICS IN CANADA

Transcription:

«RADIATION DOSE RATES FROM PATIENTS RECEIVING IODINE-131 THERAPY IN THE RABAT CHU» T.KALONJI, A.ELYAHYAOUI, S.BOUHLASSA, F.IMANI, N.BEN RAIS

INTRODUCTION

The standards in use in our service impose a five days stay for the patients having received an amount from at least 1,1 GBq. It is interresant to note that in these standards the patient is regarded as a point source of iodine 131, placed at 1 meter of distance of its close relations during eight hours per day and outputting an amount of irradiation limited to 5 msv.

It appears thus that this estimation of the duration of hospitalization takes account only of the radioactive decrease of administrered dose which depends only on the physical radioactive half-life of the iodine 131. This estimation is still used in several centers of irratherapy.

However the Advisory committee of protection against radiation (CCRP) and of the Group of the medical advisers (GCM) of CANADA recommend that the determination of radioactivity dose must take in consideration that the patient is a diffuse source (not point source), which attenuating properties are more considrable than a point source.

Taking into account these considerations, the present study aims to carryout a follow-up of dose rate of irradiation of the patient during his hospitalization, in order to appreciate with precision, the time in which it ceases to constitute a danger of irradiation for the neighbouring people.

The obtained results will make it possible to reduce the stay duration in the radio protected room and to optimize consequently the the use of human and material means of the service.

MATERIAL, PATIENT AND METHOD

MATERIAL: In this study the material used is: Two radio protected rooms equipped each one with toilets with a WC connected to the tanks of radioactivity decrease. Mural rate meter Leaded blouse The leaded folding screen A card of investigation

PATIENT: The measurements of dose rate are realized among patients treated for thyroid cancer in the service of nuclear medicine of the Avicenne hospital. 72 files were selected for this study; The patients brek down as follow: - female sex (91%), - Age in the range of 30-40years

Originating from all the areas of Morocco (90%) and the inhabitants of Rabat 10% of the sample studied.

METHOD: The selection of the population of the patients was made on the basis of following criterion: To be treated for thyroid cancer in the service of nuclear medicine of the CHU of Rabat. to have an accessible medical file;

To have transitorily stop its treatment by thyroid hormones for a least duration of 4 weeks To have made the biological chek-up of TSH us and Tg.

During the hospitalization of the pathients whose files were selected, we measured the dose rates at the 48 th,72 th and at the end of their hospitalization (at 120 th hour) Measurements are realized respectively at distance 1 meter and 2 meters from the patient

RESULTATS

DISTRIBUTION OF THE PATIENTS BY SEX

REPARTITON OF THE PATIENTS BY SLICES OF AGES 50,00% 40,00% 30,00% 20,00% 10,00% 0,00% 10-19 ans 20-29 ans 30-39 ans 40-49 ans 50-59 ans 60-69 ans 70-79 ans

LEVEL OF SOCIAL LIFE OF THE PATIENTS

PROPORTION OF THE PATIENTS AT THE METASTASES STAGE

48 th hour 72 th hour 13,086 5,529

48 th hour 72 th hour 4,592 2,079

AT THE AND OF HOSPITALISATION 2,013

DISCUSSION

The data analysis obtained show that the rate dose measured at different distances are not inversely proportional to reciprocal of the square of the distance (tables 1 and 2); This observation allows us to affirm that the patients behave like a non point source; This is due to the fact that the radioactivity injected is distributed in the blood of the examined patients.

In addition we note that the average of the dose rates measured at the 48 th hour, at a distance of at 1 meter of the patient, is about 13.08µSv/H which is approximately equal to the low threshold ( 200 MBq)

This low radioactivity at the 48 th hour is due to the fact that : The patients have all undergoes the operation of the thyroid and there is just an minor amount of thyroid parenchyma thet remains; In addition it has been known that the process of fixing iodine is disturbed on the sick or tumoral thyroid parenchyma which does not concentrate iodine, From where, only a small proportion of administered activity was fixed;

The value of this residual activity of 200 MBq measured at the 48 th hour corresponds to that authorizing the end of the hospitalization of the patient with a restriction period of 7 days. (the 97/43/EURATOM directive)

The patient leaving authorized after the 48 th hour instead of 120 th hour, has the following advantages: The service will hospitalizes 192 patients per yaer, instead of 96 patients, as it is currently the case; The reduction of the waiting period of the programmed treatments which will pass from 2 years to 1 year;

It makes it possible to avoid prolonging the isolation of the patient unnecessarily. This can influence much the moral of the patient as well as his family. Because, this protocol of insolation gives the impression to the patients that they have a threatening disease and a dangerous treatment; what justifies the resentment.

Taking into account the sociocultural conditions of our patients, the treatment in external private clinic seems not to be a possible solution.

CONCLUSION

It has been schown from this results that: 1. That it is possible: To make the available radioprotected rooms profitable at a maximum; To reduce for many patients the waiting periods of the treatment; To avoid unnecessarily prolonging insolation of the patient which can influence much more the moral of the patient as well as his family. 2. That the treatment in external private clinic is not a still possible solution.

REFERECES

1. Barrington, S.F., Kettle, A.G., O'Doherty, M.J., Wells, C.P., Somer, E.J.R., and Coakiey, A.J. "Radiation Dose Rates from Patients Receiving Iodine-131 Therapy for Carcinoma ofthe Thyroid." European Journal of Nuclear Medicine. Vol. 23, No.2, February 1996. 2. Barrington, S.F., Kettle, A.G., Thomson, W.H., Burrell, D.N., Batchelor, S., Mountford, P.J., O'Doherty, M.J. and Harding L.K. "RCP Guidelines on Radiation Protection Following Radioiodine Therapy for Thyrotoxicosis: Are they Appropriate? (abstract)". Nuclear Medicine Communications (1996) Vol. 17;275. 3. Carey, J.L., Kumpuris, T.M. and Wrobel, M.C. "Release of Patients Containing Therapeutic Dosages of Iodine-131 from Hospitals. Journal of Nuclear Medicine Technology. Vol. 23, No. 23, pp. 144-149, September 1995. 4. Caldwell, C.B. and Ehriich, L.E. Outpatient Treatment ofthyroid Cancer Using High doses oflodine 131, Canadian Association ofradiologists Journal, Oct. 1999. vol. 50 no. 5 pages 331-336. 5. Culver, C.M., Dworkin, H.J. "Radiation Safety Considérations for Post-Iodine- 131 Thyroid Cancer Therapy". Journal ofnuclear Medicine, Vol. 33, No. 7: 1402-1405, July 1992. 6. "Lignes directrices sur la gestion des patients traités à l'iode 13l", Groupe des conseillers médicaux auprès de la Commission de contrôle de l'énergie atomique, mars 1993, ÎNFO-0442.

7. Monsieurs, M., Thorons, H., Darks, R-, De Bacre, E-, De Ridder, L., De Saedeleer, C., De Winter, H., Lippens, M., Van Imschoot, S-, Wulfrank, D., Simons, M. Coordinating centre: University Hospital, Gent, Belgium. "Real-life Radiation Burden to In-living Relatives of Patients Treated with 1-131 for Benign and Malignant Thyroid Disease: a Multicentre Study in 8 Centres for Flanders (Belgium)". (Abstract # 853 - Poster Session) at 45ihAnnual Meeting ofthe Society of Nuclear Medicine, June 1998 (Toronto). 8. Radiation Protection Following lodine - 131 Therapy (Exposures Due to Outpatients or Discharged Inpatients), Luxembourg: European Commission, 1998. (Radiation Protection séries no. 97). 9. Siegel, J.A. "Outpatient Radionuclide Therapy." Proceedings of the Thirty-Fifth Annual Meeting ofthe National Council on Radiation Protection and Measurements. Proceedings No. 21 April 7-8 1999. 10. Wasserman, H.J. and Kiopper, J.F. "Analysis of Radiation Doses Received by thé Public from ml Treatment ofthyrotoxic Outpatients". Nuclear Medicine Communications (1993) 14, 756-760. 11. Working Party ofthe Radiation Protection Committee ofthe British Institute of Radiology. "Patients Leaving Hospital after Administration of Radioactive Substances." BJR Feb 1999 pp. 121 125